Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 7/20 | 0.35 |
| ▸ | RAB9A | P51151 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667482 | 1.00 | PLK1 (0.37) | PLK1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL667491 | 0.94 | PLK1 (0.35) | PLK1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL29684619 | 0.94 | PLK1 (0.35) | PLK1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL667456 | 0.92 | PLK1 (0.39) | PLK1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL29684822 | 0.92 | PLK1 (0.39) | PLK1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL667409 | 0.89 | ABCB1 (0.39) | NPC1RAB9ASMN1; SMN2MAPTABCB1 | |
| SCHEMBL29684694 | 0.89 | ABCB1 (0.39) | NPC1RAB9ASMN1; SMN2MAPTABCB1 | |
| SCHEMBL17416594 | 0.87 | PLK1 (0.36) | PLK1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17025751 | 0.87 | PLK1 (0.41) | PLK1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL10358568 | 0.86 | PLK1 (0.33) | PLK1NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406655-A | Modulation of expression of polypeptides by novel gene switch expression systems | 普瑞赛格恩公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118159653-A | Chimeric receptor therapies | 普雷西根公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4274898-A2 | CHIMERIC RECEPTOR THERAPY | Precigen, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4251278-A1 | HUMAN PAPILLOMA VIRUS VACCINES AND USES OF THE SAME FOR HPV ASSOCIATED DISEASES | Precigen, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20220220187-A1 | CHIMERIC RECEPTOR THERAPY | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2022-07-14 | — | — | US | disclosed |
| WO-2022150732-A2 | CHIMERIC RECEPTOR THERAPY | PRECIGEN, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022115470-A1 | HUMAN PAPILLOMA VIRUS VACCINES AND USES OF THE SAME FOR HPV ASSOCIATED DISEASES | PRECIGEN, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220187-A1 | CHIMERIC RECEPTOR THERAPY | HAVCR2, PTPN6, PTPN18 | PLK1 591/4885NPC1 1285/4885RAB9A 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.